A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 12, 2013, Pages 1800-1808

  Kroiss, Alexander ^a   Putzer, Daniel ^a   Frech, Andreas ^a   Decristoforo, Clemens ^a   Uprimny, Christian ^a   Gasser, Rudolf Wolfgang ^a   Shulkin, Barry Lynn ^b   Url, Christoph ^a   Widmann, Gerlig ^a   Prommegger, Rupert ^c   Sprinzl, Georg Mathias ^d   Fraedrich, Gustav ^a   Virgolini, Irene Johanna ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c Sanatorium Kettenbrücke ^*  (Austria)

^d State Clinic St Poelten   (Austria)

Author keywords

Extra adrenal paraganglioma; PET CT

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID OCTREOTIDE[1 DEXTRO PHENYLALANINE 3 TYROSINE] GA 68; 6 FLUORODOPA F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; GA(III) DOTATOC; GA(III)-DOTATOC; OCTREOTIDE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EXTRA ADRENAL PARAGANGLIOMA; FEMALE; HISTOLOGY; HUMAN; MALE; MORPHOLOGY; PARAGANGLIOMA; PET SCANNER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; CHEMODECTOMA; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; METHODOLOGY; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; YOUNG ADULT;

ADULT; AGED; DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PARAGANGLIOMA, EXTRA-ADRENAL; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84887883533     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2548-y     Document Type: Article

References (26)

1. Brink I, Hoegerle S, Klisch J, Bley TA. Imaging of pheochromocytoma and paraganglioma. Fam Cancer. 2005;4:61-8.
2. Timmers HJ, Chen CC, Carrasquillo JA, Chen CC, Whatley M, Ling A, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94:4757-67.
3. van Gils AP, van Erkel AR, Falke TH, Pauwels EK. Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities. Eur J Nucl Med. 1994;21:239-53.
4. Maurea S, Cuocolo A, Reynolds JC, Neumann RD, Salvatore M. Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. Q J Nucl Med. 1996;40:365-71.
5. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med. 2008;49:1232-7.
6. Taïeb D, Neumann H, Rubello D, Al-Nahhas A, Guillet B, Hindié E. Modern nuclear imaging for paragangliomas: beyond SPECT. J Nucl Med. 2012;53:264-74.
7. Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E, et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging. 2003;30:689-94.
8. Rufini V, Treglia G, Castaldi P, Perotti G, Calcagni ML, Corsello SM, et al. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun. 2011;32:575-82.
9. Bergström M, Eriksson B, Oberg K, Sundin A, Ahlström H, Lindner KJ, et al. In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. J Nucl Med. 1996;37:32-7.
10. Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging. 2012;39:1144-53.
11. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-18.
12. Mundschenk J, Unger N, Schulz S, Höllt V, Schulz S, Steinke R, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab. 2003;88:5150-7.
13. Timmers HJ, Taieb D, Pacak K. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44:367-72.
14. Taïeb D, Timmers HJ, Hindié E, Guillet BA, Neumann HP, Walz MK, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012;39:1977-95.
15. Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazúrová I, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49:1613-9.
16. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2000;284:3043-5.
17. Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A, et al. A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun. 2007;28:870-5.
18. Luxen A, Perlmutter M, Bida GT, Van Moffaert G, Cook JS, Satyamurthy N, et al. Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET. Int J Rad Appl Instrum A. 1990;41:275-81.
19. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology. 2009;90:167-83.
20. Tischler AS. Pheochromocytoma: time to stamp out "malignancy"? Endocr Pathol. 2008;19:207-8.
21. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25:79-83.
22. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262-9.
23. Treglia G, Cardillo G, Stefanelli A, Di Franco D, Enang GN, Giordano A, et al. Multifocal extra-adrenal paraganglioma evaluated with different PET tracers: comparison between 18F-FDG, 18F-DOPA and 68Ga DOTANOC PET/CT. Clin Nucl Med. 2013. doi: 10.1097/RLU.0b013e31827088d9.
24. Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I- metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865-73.
25. Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. (68)Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:514-23.
26. Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L- dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging. 2010;54:68-75.